Detalhe da pesquisa
1.
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Leuk Lymphoma
; 59(6): 1338-1347, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28925785